A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer

Chinese Medical Journal

Volumn 126, Issue 18, 2013, Pages 3470-3474

  Yang, Lin ^a   Song, Yan ^a   Zhou, Ai Ping ^a   Qin, Qiong ^a   Chi, Yihebali ^a   Huang, Jing ^a   Wang, Jin Wan ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Drug therapy; Oxaliplatin; S 1; Stomach neoplasms

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EVALUATION; EXPOSURE; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SKIN PIGMENTATION; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84884245742     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131009     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Rivera F, Vega-Villegas ME, López-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007; 33: 315-324.
3. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
5. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
6. Kim YH. Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat 2005; 37: 79-86.
7. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
8. Kato T, Shimamoto Y, Uchida J, Ohshimo H, Abe M, Shirasaka T, et al. Possible regulation of 5-fluorouracil-induced neuro-and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. Anticancer Res 2001; 21: 1705-1712.
9. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748-755.
10. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-172.
11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
12. Jin M, Lu H, Li J, Shen L, Chen Z, Shi Y, et al. Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. J Clin Oncol 2008; 26: 4533.
13. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
14. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol 2009; 20: 666-673.
15. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442.
16. Chi Y, Ren JH, Yang L, Cui CX, Li JL, Wang JW. Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma. Chin Med J 2011; 124: 2997-3002.
17. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 6957-6965.
18. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
19. Higuchi K, Koizumi W, Yamada Y, Nishikawa K, Gotoh M, Fuse N, et al. Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. J Clin Oncol 2013; 31: 60.
20. Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, et al. Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 2008; 98: 1034-1038.
21. Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, et al. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 892-896.
22. Li J, Yin J, Zhu X, Liu Y, Cao J, Lu F, et al. Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. Anticancer Drugs 2008; 19: 745-748.
23. Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sym SJ, et al. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2010; 65: 473-480.
24. Oh SY, Kwon HC, Jeong SH, Joo YT, Lee YJ, Cho SH, et al. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs 2012; 30: 350-356.